Difference between revisions of "Improve Identification & Data Collection for NAS"
| Line 1: | Line 1: | ||
| − | + | __NOTOC__ Return to [[ZOOM_MAP_-_Expand_Steps_to_Minimize_Opioid_Use_During_Pregnancy_or_Pregnancy_during_Opioid_Use|ZOOM MAP - Expand Steps to Minimize Opioid Use During Pregnancy or Pregnancy during Opioid Use]] <div class="wiki" id="content_view" style="display: block">__TOC__ | |
| − | = | + | = Overview = |
| − | <div class="_">One of the biggest challenges of addressing NAS is that it is not consistently identified, and collection of data and reporting is inconsistent. | + | <div class="_">One of the biggest challenges of addressing NAS is that it is not consistently identified, and collection of data and reporting is inconsistent.</div> |
| − | = | + | = Key Information = |
| − | == Indiana State Department of Health == | + | = Relevant Research = |
| − | <div class="_">In 2014, because of the high rate of opioid prescriptions, the Indiana General Assembly charged the Indiana State Department of Health (ISDH) to: develop a standard clinical definition of NAS and a standardized process of identifying it, identify the resources hospitals need to do this, and then establish a voluntary pilot program with hospitals to implement this standardized NAS identification. As of 2016, 26 of 89 Indiana Birthing Hospitals are taking part in this pilot screening program . ISDH noted that universal screening in a [[Shift_from_Punishment_to_Treatment_Approach_for_Opioid_Users|non-punitive]] environment would allow us to understand the true prevalence of Perinatal Substance Use and NAS.<sup class="reference">[1]</sup></div> <div class="_"> The Indiana State Department of Health (ISDH) established a Task Force which defined a '''standard clinical definition of Neonatal Abstinence Syndrome'''</div> | + | |
| + | = Impactful Federal, State, and Local Policies = | ||
| + | |||
| + | === Indiana State Department of Health === | ||
| + | <div class="_">In 2014, because of the high rate of opioid prescriptions, the Indiana General Assembly charged the Indiana State Department of Health (ISDH) to: develop a standard clinical definition of NAS and a standardized process of identifying it, identify the resources hospitals need to do this, and then establish a voluntary pilot program with hospitals to implement this standardized NAS identification. As of 2016, 26 of 89 Indiana Birthing Hospitals are taking part in this pilot screening program . ISDH noted that universal screening in a [[Shift_from_Punishment_to_Treatment_Approach_for_Opioid_Users|non-punitive]] environment would allow us to understand the true prevalence of Perinatal Substance Use and NAS.<sup class="reference">[1]</sup></div> <div class="_"> </div> <div class="_">The Indiana State Department of Health (ISDH) established a Task Force which defined a '''standard clinical definition of Neonatal Abstinence Syndrome'''</div> | ||
*The infant must: | *The infant must: | ||
*Be symptomatic | *Be symptomatic | ||
| Line 12: | Line 16: | ||
**A positive toxicology test '''OR''' | **A positive toxicology test '''OR''' | ||
**A maternal history with a positive verbal screen or toxicology test | **A maternal history with a positive verbal screen or toxicology test | ||
| − | + | ISDH NAS Task Force Final Report: <div class="objectEmbed">[[File/view/Neonatal_Abstinence_Syndrome_Report_Final_Report.pdf/617730023/Neonatal_Abstinence_Syndrome_Report_Final_Report.pdf|[File:http://www.wikispaces.com/i/mime/32/application/pdf.png Neonatal_Abstinence_Syndrome_Report_Final_Report.pdf]]] <div>[[File/view/Neonatal_Abstinence_Syndrome_Report_Final_Report.pdf/617730023/Neonatal_Abstinence_Syndrome_Report_Final_Report.pdf|Neonatal_Abstinence_Syndrome_Report_Final_Report.pdf]] | |
*[[File/detail/Neonatal_Abstinence_Syndrome_Report_Final_Report.pdf|Details]] | *[[File/detail/Neonatal_Abstinence_Syndrome_Report_Final_Report.pdf|Details]] | ||
*[[File/view/Neonatal_Abstinence_Syndrome_Report_Final_Report.pdf/617730023/Neonatal_Abstinence_Syndrome_Report_Final_Report.pdf|Download]] | *[[File/view/Neonatal_Abstinence_Syndrome_Report_Final_Report.pdf/617730023/Neonatal_Abstinence_Syndrome_Report_Final_Report.pdf|Download]] | ||
*989 KB | *989 KB | ||
| − | </div> </div | + | </div> </div> NAS Identification Algorithm <div class="objectEmbed">[[File/view/IPQIC_NAS_Algorithm_Version_4.pdf/617730057/IPQIC_NAS_Algorithm_Version_4.pdf|[File:http://www.wikispaces.com/i/mime/32/application/pdf.png IPQIC_NAS_Algorithm_Version_4.pdf]]] <div>[[File/view/IPQIC_NAS_Algorithm_Version_4.pdf/617730057/IPQIC_NAS_Algorithm_Version_4.pdf|IPQIC_NAS_Algorithm_Version_4.pdf]] |
*[[File/detail/IPQIC_NAS_Algorithm_Version_4.pdf|Details]] | *[[File/detail/IPQIC_NAS_Algorithm_Version_4.pdf|Details]] | ||
*[[File/view/IPQIC_NAS_Algorithm_Version_4.pdf/617730057/IPQIC_NAS_Algorithm_Version_4.pdf|Download]] | *[[File/view/IPQIC_NAS_Algorithm_Version_4.pdf/617730057/IPQIC_NAS_Algorithm_Version_4.pdf|Download]] | ||
*63 KB | *63 KB | ||
| − | </div> </div | + | </div> </div> '''''See [[ZOOM_MAP_-_Expand_Steps_to_Minimize_Opioid_Use_During_Pregnancy_or_Pregnancy_during_Opioid_Use|Adopt Universal Screening for Pregnant Women]] for more information on standardized screening and testing for NAS''''' |
| − | + | = <span style="background-color: #ffffff">Available Tools and Resources</span> = | |
| − | + | <div class="_">[[TR_-_Adopt_Universal_Screening_for_Pregnant_Women|TR_-_Adopt_Universal_Screening_for_Pregnant_Women]]</div> | |
| − | = <span style="background-color: #ffffff">Tools & Resources</span> = | ||
| − | <div class="_">[[TR_-_Adopt_Universal_Screening_for_Pregnant_Women|TR_-_Adopt_Universal_Screening_for_Pregnant_Women]] | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | </div> | ||
= <span style="background-color: #ffffff">Sources</span> = | = <span style="background-color: #ffffff">Sources</span> = | ||
| Line 41: | Line 32: | ||
#[http://www.amchp.org/programsandtopics/BestPractices/InnovationStation/ISDocs/Perinatal%20Substance%20Use.pdf [1]] | #[http://www.amchp.org/programsandtopics/BestPractices/InnovationStation/ISDocs/Perinatal%20Substance%20Use.pdf [1]] | ||
| − | </div> | + | </div> |
[[Category:Pages with broken file links]] | [[Category:Pages with broken file links]] | ||
Latest revision as of 17:17, 8 February 2021
Return to ZOOM MAP - Expand Steps to Minimize Opioid Use During Pregnancy or Pregnancy during Opioid Use
Contents
Overview
One of the biggest challenges of addressing NAS is that it is not consistently identified, and collection of data and reporting is inconsistent.
Key Information
Relevant Research
Impactful Federal, State, and Local Policies
Indiana State Department of Health
In 2014, because of the high rate of opioid prescriptions, the Indiana General Assembly charged the Indiana State Department of Health (ISDH) to: develop a standard clinical definition of NAS and a standardized process of identifying it, identify the resources hospitals need to do this, and then establish a voluntary pilot program with hospitals to implement this standardized NAS identification. As of 2016, 26 of 89 Indiana Birthing Hospitals are taking part in this pilot screening program . ISDH noted that universal screening in a non-punitive environment would allow us to understand the true prevalence of Perinatal Substance Use and NAS.[1]
The Indiana State Department of Health (ISDH) established a Task Force which defined a standard clinical definition of Neonatal Abstinence Syndrome
- The infant must:
- Be symptomatic
- Have two or three consecutive modified Finnegan scores equal to or greater than a total of 24
- And have one of the following:
- A positive toxicology test OR
- A maternal history with a positive verbal screen or toxicology test
Available Tools and Resources
Sources
- [1]
